@article{3f18c82f8e154693a0e7ecb2bd085b5a,
title = "IL-8/CXCR2 signalling promotes cell proliferation in oesophageal squamous cell carcinoma and correlates with poor prognosis",
abstract = "Background/Aim: The inflammatory cytokine IL- 8 and its receptor CXCR2 are key signalling pathway molecules in cancer development. We hypothesized that IL- 8/CXCR2 signalling promotes tumour progression in oesophageal squamous cell carcinoma (ESCC) patients. Materials and Methods: We examined the relationship between IL-8/CXCR2 expression and clinicopathological factors by immunohistochemistry in samples from 63 patients with resectable ESCC. The effects of IL-8/CXCR2 signalling on cell proliferation and gene expression were examined in vitro and in vivo using ESCC cell lines. Results: Increased IL-8/CXCR2 signalling was associated with shorter overall survival (p<0.05) and recurrence-free survival (p<0.05) in ESCC patients. Multivariate analysis identified IL-8/CXCR2 expression as a prognostic factor for surgically treated ESCC (p<0.05). In vitro, IL-8 exposure or over-expression significantly enhanced ESCC cell proliferation. SB225002, a CXCR2-specific antagonist, and IL-8 siRNA significantly suppressed cell proliferation. Conclusion: IL-8/CXCR2 expression is an independent prognostic factor for surgically treated ESCC, and IL-8/CXCR2 signalling contributes to ESCC cell proliferation.",
keywords = "CXCR2, Cell proliferation, Chemokine, IL-8, Oesophageal squamous cell carcinoma",
author = "Masazumi Inoue and Hiroya Takeuchi and Sachiko Matsuda and Tomohiko Nishi and Kazumasa Fukuda and Rieko Nakamura and Tsunehiro Takahashi and Norihito Wada and Hirofumi Kawakubo and Yuko Kitagawa",
note = "Funding Information: The Authors would like to thank Yuki Nakamura and the Collaborative Research Resources Department, School of Medicine, Keio University for technical assistance. The Authors also thank Edanz Group (https://en-author-services.edanzgroup.com/) for editing a draft of this manuscript. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan (grant numbers: 24591960, 21591712, and 16K19954). Funding Information: Dr. Kitagawa reports grants and personal fees from ASAHI KASEI PHARMA CORPORATION, grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants and personal fees from CHUGAI PHARMACEUTICAL CO., LTD., grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD, grants from TSUMURA & CO., grants from ONO PHARMACEUTICAL CO., LTD., grants from Takeda Pharmaceutical Co., Ltd., grants from MEDICON INC., grants from Yakult Honsha Co. Ltd., grants from Otsuka Pharmaceutical Factory Inc., grants from EA Pharma Co., Ltd., grants from Eisai Co., Ltd., personal fees from SHIONOGI & CO., LTD., personal fees from Nippon Covidien Inc., outside the submitted work. Publisher Copyright: {\textcopyright} 2021 International Institute of Anticancer Research. All rights reserved.",
year = "2021",
month = feb,
doi = "10.21873/ANTICANRES.14830",
language = "English",
volume = "41",
pages = "783--794",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",
}
